Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2009; Notice dated July 15, 2009.
Context: The filing discloses a new issue of ordinary shares pursuant to Section 708A(5) of the Corporations Act. The company is a foreign private issuer filing under Form 20-F.
Key Financial Metrics and Capital Structure
Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital disclosure notice, not a financial results report.
Capital Structure Update:
- Securities Issued: 180,666 Ordinary Shares (PBT).
- Issue Price: $Nil (issued upon exercise of options).
- Total Quoted Securities: 202,891,139 Ordinary Shares (including the new issue).
- Unlisted Options: Multiple tranches exist with varying exercise prices (ranging from $Nil to AUD$0.50) and expiry dates between 2009 and 2014.
Material Changes
The primary material change is the increase in the number of quoted ordinary shares from approximately 202.7 million to 202.9 million following the issuance of 180,666 shares. These shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act, as they resulted from the exercise of options under the Employee Incentive Scheme and Consulting Agreements.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the company intends to apply to the Australian Stock Exchange (ASX) for quotation of the newly issued shares. The dividend policy remains unchanged.
Risks and Contingencies: The filing includes standard warranties to the ASX regarding compliance with the Corporations Act and indemnification against claims arising from breaches of these warranties. No specific operational risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the total number of outstanding options and their respective exercise prices to assess potential future dilution.
- Confirm the exact date the new shares were admitted to quotation on the ASX.
- Review the company's most recent Form 20-F or financial statements for actual revenue, cash flow, and liquidity positions, as this filing does not contain them.
- Check for any subsequent filings regarding the status of the unlisted options expiring in late 2009 (e.g., PBTAA, PBTAC).